Harold Edward Fleming - 17 Jun 2026 Form 4 Insider Report for Sionna Therapeutics, Inc. (SION)

Reporting relationship: Director
Issuer ticker: SION
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 17:35:40 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: By: Jennifer Fitzpatrick, Attorney-in-Fact For: Harold Edward Fleming

Key filing fact

Harold Edward Fleming filed Form 4 for Sionna Therapeutics, Inc. (SION) on 18 Jun 2026.

Key facts

This page summarizes Harold Edward Fleming's Form 4 filing for Sionna Therapeutics, Inc. (SION).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 17:35.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857250 Primary reporting owner

Fleming Harold Edward

Relationship: Director
Address: C/O SIONNA THERAPEUTICS, INC., 21 HICKORY DRIVE, SUITE 500, WALTHAM
Signature: By: Jennifer Fitzpatrick, Attorney-in-Fact For: Harold Edward Fleming
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SION transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +17,340
Change %
Price: $0.000000^*
Shares after: 17,340
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,340
Exercise price: $36.73
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

Footnote F2

This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.